Copanlisib-Associated Skin Toxicity: A Peculiar Case of Copanlisib-Induced Skin Rash in a Patient with Refractory Follicular Lymphoma

Download Citation in txt Download Citation in bib Download Citation in ris

Author Info

Dawood Findakly Surabhi Amar

Corresponding Author

Dawood Findakly
Creighton University School of Medicine, Omaha, Nebraska, USA

A B S T R A C T

Background: Phosphatidylinositol 3-kinase (PI3K) is an essential target in lymphoid tumors therapy. Copanlisib is a novel class of medication that targets PI3K and used for the treatment of relapsing or refractory B-cell lymphomas. Case Presentation: A 42-year-old woman presents to our hospital for worsening abdominal pain. Examination pertinent for axillary lymphadenopathy, and abdominal ascites. CT chest, abdomen and pelvis reported multiple lung nodules, pleural effusions, extensive retroperitoneal lymphadenopathy, and peritoneal carcinomatosis. Lymph node and bone marrow biopsies confirmed B-cell follicular lymphoma and fluorescent in situ hybridization (FISH) testing was positive for translocation t(14:18). Her disease was refractory to multiple chemotherapy regimens. Thus, initiated copanlisib therapy with a remarkable response, but the patient developed a diffuse maculopapular rash and skin biopsy-proven to be drug rash. Therefore, copanlisib was discontinued. Conclusion: Here, we report a case of a middle-aged woman who developed a rash after the fifth cycle of copanlisib therapy. This case report will create awareness of evolving possible side effects in this novel chemotherapeutic agent.

Article Info

Article Type

Case Report

Publication history

Received: Mon 02, Mar 2020
Accepted: Mon 30, Mar 2020
Published: Tue 31, Mar 2020

Copyright

© 2023 Dawood Findakly. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.03.07